No Data
No Data
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating
Beam Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 4:30 PM ET
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Beam Therapeutics Advances Base Editing Portfolio
Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101